GlassScriptPhysician profile
Lily Talakoub
NPI 1801929773
$18,267.24
in general payments reported to CMS, 2019-2025
35 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,964 · 2021: $141 · 2022: $550 · 2023: $503 · 2024: $312 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,683.52 | 2019-2021 | |
| Merz North America, INC. | $5,660.57 | 2019-2023 | Xeomin |
| Galderma Laboratories, L.P. | $2,497.20 | 2019-2025 | Aklief, Oracea, Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $275.94 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Incyte Corporation | $250.54 | 2021-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $245.90 | 2021-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $185.07 | 2019-2024 | Otezla, Enbrel |
| Encore Dermatology INC. | $182.86 | 2019-2020 | |
| Strata Skin Sciences, INC. | $141.65 | 2022 | |
| Mayne Pharma Commercial LLC | $138.38 | 2019 | |
| Janssen Biotech, INC. | $112.81 | 2022-2025 | Simponi Aria, Simponi, Stelara |
| Sientra, INC. | $96.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.62 | 2019-2025 | |
| Leo Pharma INC. | $84.00 | 2019-2022 | |
| Abbvie INC. | $76.39 | 2022-2023 | Rinvoq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $59.81 | 2022-2023 | |
| Lilly USA, LLC | $53.45 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Almirall LLC | $53.18 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.00 | 2023 | Libtayo |
| Arcutis Biotherapeutics, INC. | $35.80 | 2024-2025 | Zoryve |
| Epi Health, LLC | $33.82 | 2020-2021 | |
| Pfizer INC. | $31.93 | 2019-2022 | |
| Glenmark Therapeutics INC. | $30.00 | 2019 | |
| Journey Medical Corporation | $26.99 | 2022 | |
| Celgene Corporation | $22.87 | 2019 | |
| Ucb, INC. | $21.98 | 2025 | Bimzelx |
| Promius Pharma LLC | $18.61 | 2019 | |
| Dermira, INC. | $17.99 | 2019 | |
| Vyne Pharmaceuticals INC. | $17.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.08 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.52 | 2025 | |
| Mission Pharmacal Company | $14.47 | 2022 | |
| Verrica Pharmaceuticals INC. | $13.83 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $13.74 | 2023 | Vtama |
| Biofrontera INC. | $9.61 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Talakoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.